Geordie Shore star Charlotte Crosby has become the latest person to sign up to the Anthony Nolan bone marrow register

Geordie Shore star Charlotte Crosby has spat out her support for a baby in need of a life-saving operation.

Charlotte has signed up with the Anthony Nolan Trust after reading about the plight of nine-month-old Joey Ziadi, who is suffering from a rare blood disorder that affects one in nine million people.

The tot from Northampton needs a lifesaving transplant but has not yet found a matching donor so Charlotte has enlisted her 1.89m twitter followers to join the cause.

After hearing about Joeys plight, Charlotte tweeted a selfie with her Anthony Nolan spit kit - the simple piece of equipment which allows people to leave a DNA sample and go on the bone marrow donor register.

She said: I saw the gorgeous Joey Ziadi in the news and I couldnt believe it when I heard how ill he was and that only one in nine million people have his condition I felt like crying. I knew I had to do something, but I didnt know how to help.

When I found out how simple it was to sign up to the Anthony Nolan register, I didnt have to think about it. I just thought Its so easy, why doesnt everyone do this?

Anthony Nolan saves lives by matching people willing to donate their bone marrow or blood stem cells to patients in need of a transplant.

The charity also needs more young men to sign up, as they are most likely to be chosen to donate but make up just 14% of the register. Charlotte said: I was quite shocked that young lads are so underrepresented on the register though. Come on lads, just sign up online and spit into a tube! Im doing it, and I just hope one day I have the chance to save a life.

Joey was diagnosed with an extremely rare blood disorder Diamond Blackfan Anaemia in February. His family have been campaigning to recruit more potential donors to the Anthony Nolan donor register after being told that his best hope of a cure is a bone marrow transplant from a stranger.

Read the original post:
Charlotte Crosby helps young boy in need of bone marrow transplant

Recommendation and review posted by Bethany Smith

Contact Information

Available for logged-in reporters only

Newswise New York, NY (June 30, 2014) By switching off a single gene, scientists at Columbia Universitys Naomi Berrie Diabetes Center have converted human gastrointestinal cells into insulin-producing cells, demonstrating in principle that a drug could retrain cells inside a persons GI tract to produce insulin.

The new research was reported today in the online issue of the journal Nature Communications.

People have been talking about turning one cell into another for a long time, but until now we hadnt gotten to the point of creating a fully functional insulin-producing cell by the manipulation of a single target, said the studys senior author, Domenico Accili, MD, the Russell Berrie Foundation Professor of Diabetes (in Medicine) at Columbia University Medical Center (CUMC).

The finding raises the possibility that cells lost in type 1 diabetes may be more easily replaced through the reeducation of existing cells than through the transplantation of new cells created from embryonic or adult stem cells.

For nearly two decades, researchers have been trying to make surrogate insulin-producing cells for type 1 diabetes patients. In type 1 diabetes, the bodys natural insulin-producing cells are destroyed by the immune system.

Although insulin-producing cells can now be made in the lab from stem cells, these cells do not yet have all the functions of naturally occurring pancreatic beta cells.

This has led some researchers to try instead to transform existing cells in a patient into insulin-producers. Previous work by Dr. Accilis lab had shown that mouse intestinal cells can be transformed into insulin-producing cells; the current Columbia study shows that this technique also works in human cells.

The Columbia researchers were able to teach human gut cells to make insulin in response to physiological circumstances by deactivating the cells FOXO1 gene. Accili and postdoctoral fellow Ryotaro Bouchi first created a tissue model of the human intestine with human pluripotent stem cells. Through genetic engineering, they then deactivated any functioning FOXO1 inside the intestinal cells. After seven days, some of the cells started releasing insulin and, equally important, only in response to glucose.

Continue reading here:
It May Take Guts to Cure Diabetes

Recommendation and review posted by Bethany Smith

Contact Information

Available for logged-in reporters only

Newswise Philadelphia, June 30, 2014 In the first genome-wide analysis of postsurgical pain in children, pediatric researchers identified variations in genes that affect a childs need for pain-control drugs. The findings suggest that at some point physicians may calibrate pain-medication dosages according to a childs individual genetic makeup.

Although this research is only a first step for our team, it provides tremendous new insight into the biological mechanisms and brings us a little closer to personalizing medicine for pain control, said Scott D. Cook-Sather, M.D., a pediatric anesthesiologist at The Childrens Hospital of Philadelphia (CHOP). He is co-first author with CHOP statistician Jin Li, Ph.D., and is the corresponding author of the study.

Cook-Sather and colleagues published the study online June 9 in the journal Pain. He collaborated with Hakon Hakonarson, M.D., Ph.D., director of CHOPs Center for Applied Genomics, and the senior author of the study.

The study team performed a genome-wide association study (GWAS) of more than 600 children between ages 4 and 18 who had tonsils and adenoids removed in day surgery procedures. The retrospective study analyzed whether gene variants were associated with the need for higher or lower than average dosages of morphine for pain control. The researchers also analyzed genetic links to postoperative pain scores.

The GWAS identified one gene location linked to increased morphine requirement: the TAOK3 locus, a site not previously linked to morphine sensitivity. Genes within the TAOK3 locus carry the code for a protein with a key role in signal transduction for many cell types, including neurons involved with transmitting the sensation of pain.

It makes sense that genes related to signaling systems would modify how patients feel pain and respond to analgesics, said Cook-Sather. Follow-up studies are necessary to identify the fundamental neurobiology and details of the mechanisms involved.

While scientists already know that morphine works by binding to specific opioid receptors in the nervous system, added Cook-Sather, we dont know exactly why there is, in this setting, a tenfold variation in how much morphine patients require for pain relief. The study team found that two single-base gene variants at the TAOK3 locus were associated with approximately 8 percent of that tenfold variance in morphine requirement, comparable to that portion of the variance associated with age, body mass and overall health status combined.

Cook-Sather explained that multiple genes are assumed to contribute to these analgesic effects, and that further investigations, with larger numbers of patients, are needed to understand and prioritize the full array of genes that modify morphine response.

Read the rest here:
Gene Variants Found That Increase Pain Sensation After Common Childhood Surgery

Recommendation and review posted by Bethany Smith

The Courier Your Messenger For The River Valley

Dr. Cole taught economics at ATU for 37 years retiring in 2007. He served as Department Head in the Business and Economics Department from 1976-80. When the School of Business was formed in 1987, he was named Dean and served in that capacity until 1994. He was instrumental in developing a strategic plan and laying the foundation for international accreditation of the School of Business. In addition to his teaching and administrative duties, Dr. Cole participated in professional organizations where he presented papers at national and regional meetings as well as published many articles. His insatiable appetite for learning led him to many conferences and meetings around the world.

During his early years, Gene Cole lived at St. Josephs in North Little Rock. He attended Subiaco Academy and then graduated from Benton High School in 1955. He attended Southern State College where he played football. For a time Gene worked as a sales representative for Arkansas Louisiana Gas Company. A transfer to Russellville and the opportunity to take classes at ATU started his career change. He earned a B.S. degree in 1969 and then went on to University of Arkansas, Fayetteville, where he earned a Master of Arts (1970) and a Ph.D. (1976) in economics.

In addition to being a strong academician, Gene Cole was an athlete who was involved in various sports in both high school and college. He refereed both football and basketball games for many years. He treasured his lifelong friendships and adventures and often spoke of his days at Benton High School and Southern State College.

Family was the center of Gene Coles life. He was involved in all aspects of his childrens lives whether it was sports, scouts, dance, education or parties. His subtle sense of humor and practical jokes kept them entertained. His interest in family extended beyond his immediate household. One of his passions was genealogy. He published a book, The Cole Family of Green County, Arkansas and discovered many facts, some good and some not so good from his extensive research. His slide presentations and vocal narratives about the Cole family provided entertainment at family reunions, which he loved to organize. He and Cathie traveled extensively doing genealogy research.

Gene Cole was preceded in death by his wife of 49 years, Mary Catherine Cathie Cole; parents, Nan Nolan and O. J. Mutt Wilhite and Elva and Raymond Louis Cole and sister, Judy Speights.

He is survived by three daughters and two sons: Dana and Eugene Duvall of Atkins, Kim Drumm and Bruce Carlson of Lafayette N.Y., Suzy and Scott Griffin of Russellville, Johnnie and Amanda Cole of Broken Arrow, Okla., and Mike and Barbara Cole of Russellville; nine grandchildren: Trevor and Brooke Taylor, Josh Drumm, Kelli and Zach Moore, Brittany Drumm, Jasper Cole, Cody Duvall, Emily and Kalob Shipley, Reed Cole and Cole Duvall; four great-grandchildren: Dakota Shipley, Gemma Taylor, Kolton Shipley and Ethan Shipley. Also surviving are five sisters and one brother, Betty Jo Jones, Janet Bray, Patty Cole Niebling, Saline Sinkoe, Nancy Bartlett and Louie Cole. In addition, there are numerous nieces, nephews, cousins and a host of friends.

Gene Cole was a kind person who loved life and his family. His always hopeful and positive outlook will continue to guide and influence them throughout their lives.

Following a private burial under the direction of Shinn Funeral Service of Russellville, there will be a public reception to memorialize Gene Coles life and legacy from 1-3 p.m. on Monday, June 30, 2014, in Williamson Dining Hall at Arkansas Tech University. Memorials in his name may be made to ATU College of Business Endowment Fund, 8820 Tech Lane, Russellville AR 72801.

The online obituary and guestbook are available at http://www.shinnfuneral.com.

Continued here:
Obituary: Gene Cole

Recommendation and review posted by Bethany Smith

Irvine, CA and Annapolis Junction, MD (PRWEB) June 30, 2014

Proove Biosciences, the commercial and research leader in personalized medicine, presented research and exhibited the companys genetic testing products and services at the 2014 Florida Academy of Pain Medicine(FAPM) Scientific Meeting. The meeting was held in conjunction with the Florida Society of Physical Medicine and Rehabilitation and the American Academy of Regenerative Orthopedic Medicine.

The research studies that we showcase illustrate how genetic testing can be an integral part of an effective personalized pain treatment regimen, stated Brian Meshkin, President of Proove Biosciences. Failed treatments for uncontrolled chronic pain lead to escalating healthcare costs and unnecessary patient suffering.

FAPMs meeting is the premier event for pain treatment professionals, researchers, and practitioners. The conference is designed to promote a better understanding of pain and features the latest products and techniques for pain management and diagnosis. In addition to scientific sessions, this years meeting included three hands-on preconference workshops and panel discussions about the legal and political challenges facing the practice of medicine.

Florida has a startlingly high rate of prescription drug abuse and overdose deaths, and both the State and FAPM are on the cutting edge of developing new methods to combat the problem, Meshkin said. Prooves products and services are utilized throughout the country including Florida to help doctors efficiently prescribe pain treatments and lower healthcare costs.

About Proove Biosciences

Our mission is to change the future of medicine by providing proof to improve healthcare decisions. We envision a future when clinicians will know how patients are likely to respond to medications before writing a prescription. We believe such knowledge can be provided by genetic testing: Using a simple cheek swab, Proove performs proprietary genetic tests in its CLIA-certified laboratory. Healthcare providers use the results to evaluate how their patients will metabolize medications, and to screen for the likelihood of medication misuse.

Founded in 2009 with offices in Southern California and the Baltimore-Washington metropolitan area, Proove Biosciences is the leader in genetics-related personalized pain medicine research with hundreds of clinical research sites across the U.S. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).

Read more:
Proove Biosciences Presents Research at the Florida Academy of Pain Medicines 2014 Annual Scientific Meeting

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

30-Jun-2014

Contact: Kathryn Ruehle kruehle@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, June 30, 2014St. John's wort is the most frequently used complementary and alternative medicine (CAM) treatment in the U.S. for depression and similar psychiatric disorders. The many commonly prescribed medications that St. John's wort can interact withsometimes with serious consequences such as serotonin syndrome or heart diseaseare reviewed in The Journal of Alternative and Complementary Medicine, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The article is available free on The Journal of Alternative and Complementary Medicine website.

In the article "Use of St. John's Wort in Potentially Dangerous Combinations", Scott Davis, Steven Feldman, MD, PhD, and Sarah Taylor, MD, Wake Forest Baptist Medical Center, Winston-Salem, NC, present the results of a large-scale search of a national medical database across 17 years to assess how often St. John's wort is prescribed and taken with other medications that may result in adverse reactions, such as oral contraceptives, selective serotonin reuptake inhibitors (SSRIs), blood thinners, chemotherapy medicines, digoxin, statins, immunosuppressants, or HIV medicines, for example.

About the Journal The Journal of Alternative and Complementary Medicine is a monthly peer-reviewed journal publishing observational, clinical, and scientific reports and commentary intended to help healthcare professionals and scientists evaluate and integrate therapies into patient care protocols and research strategies. Complete tables of content and a sample issue may be viewed on The Journal of Alternative and Complementary Medicine website.

About the Publisher Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Alternative & Complementary Therapies, Medical Acupuncture, Brain and Gut, and Journal of Medicinal Food. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers.

Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215 Phone: (914) 740-2100 (800) M-LIEBERT Fax: (914) 740-2101 http://www.liebertpub.com

Contact: Kathryn Ruehle, Mary Ann Liebert, Inc., (914) 740-2100, kruehle@liebertpub.com

###

Read this article:
St. John's wort can cause dangerous interactions with many common medications

Recommendation and review posted by Bethany Smith

Abraham Hicks - Genetics and Inherited Diseases
Special Subjects Series (full albums in playlists) For more information on Abraham, Esther Jerry Hicks visit http://www.abraham-hicks.com You can also support Abraham-Hicks Foundation and purchase...

By: SecretsOfLife

Read more here:
Abraham Hicks - Genetics and Inherited Diseases - Video

Recommendation and review posted by Bethany Smith

Once upon a time, a ragtag bunch of Swiss scientists were hiking along the Alps when they happened upon a tree of apples so rare and spectacular that the fruit could sit for months without withering and even heal its own bruises if dropped. Naturally, their first thought was to take this magical fruit, cut it up, and put it all over their scientist faces to see how pretty it made them.

If that sounds a little too much like a fairy tale, that's because (I'm pretty sure) it is. But, the key elements are real. PhytoCellTec Malus Domestica, a stem cell derived from the Uttwiler Spatlauber apple, has become one of the buzziest skin-care ingredients of the last few years and with good reason. Because, if you follow those scientists' lead and put them all over your face, these crazy Swiss cells will indeed make you super, duper pretty.

I'd read a little of the hype around Swiss-apple stem cells on this and other sites, but the term always flew over my head and into the realm of Crazy Skin Products That Cost More Than A Car. Maybe Gwyneth and Kate Middleton can spend their pocket money on fairy-tale-science skin care, but I have a cat to support.

Then, last month on vacation in Vienna, I spotted a jar of cream labeled "Swiss Apple Formula" at a Marionnaud (kind of like European Sephora). And, y'know how sometimes foreign money doesn't feel like actual money? And, foreign beauty products always seem better than the ones you can get back home? Right, so I bought it. Plus, the matching serum.

Smash cut to the next morning when I awoke, jet-lagged and haggard but no! Jet-lagged, yes, but only haggard on the inside! My face looked as though it had slept for 11 hours and not drunk four glasses of wine with dinner. I stared at my face in the mirror and then stared at it in that crazy, magnified mirror hotels sometimes stick in the bathroom in case you'd like to really see just how huge and sun-damaged your pores are. Normally, I toss a towel over that thing lest I wind up diagnosing each new freckle as malignant skin cancer, but this morning I got up close and personal with a very happy face. It's not that it was suddenly zit and line-free, but it was calm and even. On day one it was the kind of calm and even that only I really noticed, but after a week, that changed.

I tracked down one of the most popular products in the U.S.: Emerge Labs Swiss Apple Stem Cell Serum just to make sure it wasn't the placebo effect or my magical thinking around European skin-care products. The Emerge Labs Serum (which I paired with its stem-cell moisturizer for extra stem-celliness) proved just as effective. As an added bonus, the moisturizer contains SPF 30, so I felt fully protected when the unthinkable happened I went without makeup.

A couple of weeks into using this stuff, my BB cream ran out. I don't wear a ton of it, but I normally need at least a little light face coverage, just to even things out. My nose gets red from sneezy allergies, and my aforementioned large pores are, well, quite large. But, everything seemed to just chill the hell out after a few weeks with the Swiss-apple regimen. Any discoloration seemed to even out, and I had not a blemish in sight. Even better, my skin felt constantly hydrated, but not at all greasy. I might dust on some pressed powder, but I've yet to hit Sephora for a BB refill. And, not that I'm counting, but I'm totally up to FIVE individual wow-your-skin-looks-great compliments. One friend asked if I was pregnant, so it's possible I'm too glowy now.

Since it's been just over a month, I can't speak to long-term anti-aging effects except to say that J.Lo apparently uses this product, and at 44, she looks younger than her own children. Frankly, even if it was only this magical in the short term, I still think Swiss-apple stem cells are totally worth it. PhytoCellTec is not a cheap ingredient and so neither are most of the products that contain it. But, on balance, I think having the kind of skin that lets me feel confident walking around with less makeup even no makeup is a pretty great investment.

Link:
Swiss Apple Stem Cells - Emerge Labs Skin Care

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

19-Jun-2014

Contact: David McKeon DMcKeon@nyscf.org 212-365-7440 New York Stem Cell Foundation

NEW YORK, NY (June 18, 2014) Induced Pluripotent Stem Cells (iPS) hold enormous potential to unravel the mechanisms of human illness and to develop new therapeutics. Until now, there has been no easily searchable database for investigators to find and share these important resources. This has been a major obstacle to the implementation of iPS technology.

Recognizing the research potential of shared iPS cell lines, the New York Stem Cell Foundation (NYSCF) Research Institute and the eagle-i Network will make NYSCF iPS cell lines and related information available to the public on a user-friendly, web-based, searchable database. The database (called the Induced Pluripotent Stem Cell database) will help scientists find valuable resources, enabling collaboration, preventing duplicative work, and ultimately accelerating research.

NYSCF and eagle-i will establish an open access repository of information on large numbers of iPS cell lines. eagle-i will display information as linked open data, enabling discovery by any third party search engine. NYSCF derives hundreds of iPS cell lines from skin samples of patients with a wide variety of diseases using the NYSCF Global Stem Cell ArrayTM technology, an automated platform for high-throughput iPS cell production and differentiation. Scientists will be able to search for NYSCF iPS cell lines under several categories including disease, how the cells were reprogrammed, and patient age at the time the sample was collected.

"This important tool should have significant impact on the science community," said Lee Nadler, principal investigator of Harvard Catalyst and eagle-i. "I'm thrilled that we will contribute to this partnership by creating a user-friendly, searchable database for the iPS cell lines that NYSCF has produced, enabling researchers to search for available lines on an open access platform. The opportunities this will create are tremendous."

"We were very excited to develop this resource for stem cell scientists," said Susan L. Solomon, NYSCF Chief Executive Officer. "It is important to have open access to available resources and this collaboration with eagle-i is a prime example of interdisciplinary teams working together to provide this for the scientific community."

The alpha version of the website will be presented during the International Society for Stem Cell Research (ISSCR) Annual Conference in Vancouver, Canada in June 2014. Future versions of the database will include genomic and other clinical and cellular phenotype information, including a mechanism that will allow scientists to order lines directly from the website. Soon, NYSCF and eagle-i will invite other institutions from around the world to join this collaboration and contribute their iPS cell lines to the Induced Pluripotent Stem Cell database, creating an even more robust research tool.

At the ISSCR Conference this week, Richard V. Pearse, PhD, from eagle-i will be at poster F-2245 during poster session III and NYSCF will be at booth 918 with information pertaining to this new initiative.

The rest is here:
NYSCF and eagle-i Network co-develop iPS cell database

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

29-Jun-2014

Contact: Karen Teber km463@georgetown.edu Georgetown University Medical Center

WASHINGTON For a rare form of cancer called thymoma, researchers have discovered a single gene defining the difference between a fast-growing tumor requiring aggressive treatment and a slow-growing tumor that doesn't require extensive therapy.

Thymoma is a cancer derived from the epithelial cells of the thymus, an organ critical to the lymphatic system where T-cells, or so-called "killer cells," mature. Very little is known about the role of the gene mutation GTF2l in human tumors, but scientists from Georgetown Lombardi Comprehensive Cancer Center and the National Cancer Institute say almost all indolent (slow growing and non-aggressive) forms of thymoma they tested have the mutation. They report their finding in the ?? issue of Nature Genetics.

"Indolent thymomas seldom become aggressive, so the discovery that a single gene can identify tumors that do not need aggressive care is an important development for our patients," says the study's senior investigator, Giuseppe Giaccone, MD, PhD, associate director for clinical research at Georgetown Lombardi.

In addition to the clinical implications, the study is important because "it is highly unusual to find a single mutated gene that can define a class of tumors," he said. "Usually a substantial number of genes are involved. In fact, we also found that the more aggressive thymomas express well-known cancer genes found in other tumors which might give us clues about novel treatment of these cancers."

The thymus is located in the chest behind the breastbone. Thymoma and a second type of cancer of the thymus called thymic carcinoma are rare. According to the National Cancer Institute, these cancers counted together make up for only .2 to 1.5 percent of all cancers one case occurs in about every 700,000 individuals.

Most of the diagnosed patients have surgery, but, depending on the presumed aggressiveness of the cancer, some patients will have radiation and/or chemotherapy in addition or instead of surgery. "The use of these treatments in thymomas is controversial, because we know some patients don't need aggressive therapy, but until now, there's not been a clear way to know who those patients are," Giaccone says.

###

Read the original post:
A single gene separates aggressive and non-aggressive lymphatic system cancer

Recommendation and review posted by Bethany Smith

Peter Singer Interview, University of Vienna
philosopher Peter Singer pays a visit to Erwin Lengauer of the ethics department at the University of Vienna on June 21, 2014. He talks with Kay Peggs about the history of his book "Animal...

By: Kattamedia

View post:
Peter Singer Interview, University of Vienna - Video

Recommendation and review posted by Bethany Smith

Published: Sunday, June 29, 2014 at 4:47 p.m. Last Modified: Sunday, June 29, 2014 at 4:47 p.m.

But their work is not destined for commercialization, due to a lack of financial backing and interest in getting these products through all the regulations necessary to put them on the path to the local supermarket and our dinner tables.

Public opinion is having a detrimental effect on research, scientists say, because growers in Florida dont want to invest the millions it would take to push GMOs short for genetically modified organisms through the federal regulatory process for fear the public wont buy them.

People are afraid, they dont understand why, they are just told they should be afraid of genetically engineered products, said Sam Hutton, a plant scientist specializing in tomato genetics at the Gulf Research and Education Center in Wimauma, located east of Interstate 75 between Tampa and Bradenton. The anti-GMO crowd screams really loud, and there is a lot of fearmongering. It sounds bad to people who dont understand the science.

Very few of the whole foods that consumers buy are genetically modified. Less than 1 percent of genetically modified foods are eaten whole, some sweet corn, papaya and squash, scientists say.

The bulk of genetically modified foods 75 percent are corn and soybean crops used in livestock feed, researchers say. Some genetically modified crops are used to make industrial chemicals as well starch, high fructose corn syrup, lecithin, vegetable oil and protein extracts that go into the processed foods that are colorfully packaged and found in the center aisles of the neighborhood grocery store.

None of the genetically modified corn or soybeans are grown in Florida, scientists say.

We dont have much genetically modified acreage in Florida, said Kevin Folta, professor and chairman of UFs Horticultural Sciences Department.

Folta recently organized and conducted a seminar on genetic engineering or transgenics to dispel misperceptions about genetic modification.

The speakers at the seminar, which was held in Emerson Alumni Hall at UF, addressed their comments to an audience of about 60 most of them fellow researchers and graduate students. Folta was well aware they were preaching to the choir.

Continued here:
Genetically modified foods face hurdles

Recommendation and review posted by Bethany Smith

Genetics Antenatal Counselling- DOWN #39;S SYNDROME
Visit http://www.csasmartgroup.com to get all the materials you need to ROCK your consultations! Get your FREE Training Video Series - http://www.csasmartgro...

By: CSASmartGroup

Original post:
Genetics Antenatal Counselling- DOWN'S SYNDROME - Video

Recommendation and review posted by Bethany Smith

Attack of the B-Team #18 [Minecraft][Advanced Genetics]
: http://www.attackofthebteamwiki.com/wiki/Advanced_Genetics KZee Instagramhttp://instagram.com/happykzee kzee: https://www.facebook.com...

By: K Zee

Read more:
Attack of the B-Team #18 [Minecraft][Advanced Genetics] - Video

Recommendation and review posted by Bethany Smith

Ann Arbor-based RetroSense Therapeutics LLC plans to start human trials of a gene-based therapy next year, and if those trials go as animal trials have gone, those blinded by degenerative eye diseases will regain some of their vision.

What seemed more like an interesting science experiment four years ago than a real company -- can a light-sensing gene that helps pond scum find sunlight also help the blind see? -- is attracting interest and venture capital as it gears up for human trials.

The therapy is based on the photosensitivity of a gene called channelrhodopsin-2. This gene allows blue-green algae to detect where the sun is shining on a pond so they can move in its direction and convert light to energy through photosynthesis.

When the gene, which is inside a cultured medium called a vector, is injected into the eye, previously non-photosensitive retinal cells are converted into photosensitive cells, allowing limited vision. RetroSense and its research partners have tested mice, rats and nonhuman primates, with all species showing a return of some vision following treatment, said founder and CEO Sean Ainsworth.

As a result, the company has just completed raising a venture capital round of $2.4 million, led by a San Diego firm, Nerveda LLC, and is close to agreeing on terms of a follow-on round of $5 million or more, Ainsworth said.

Those rounds will fund Phase 1 U.S. Food and Drug Administration trials next year and the first half of Phase 2 trials.

Fundraising has been sparked because of large recent deals involving other biotech firms and by RetroSense's success in animal trials for its lead product, a biologic with the working name of RST-001.

RetroSense CEO Sean Ainsworth

Ainsworth founded RetroSense in 2010 after licensing the work of Wayne State University researcher Zhuo-Hua Pan. He laid out the company's plans to a standing-room-only crowd at the recent Michigan Growth Capital Symposium in Ypsilanti, which drew venture capitalists and angel investors from around the country to hear pitches for capital from 32 Midwest firms.

Ainsworth said that if what has worked in animals works in patients taking part in the upcoming trials, at least some black-and-white vision will be restored to those blinded by such diseases as retinitis pigmentosa and dry age-related macular degeneration.

Read this article:
Gene therapy for blindness gets attention of investors

Recommendation and review posted by Bethany Smith

Dr Lox Stem Cell Therapy WFLA News 8
Dr. Lox | http://www.drlox.com | 727-462-5582 (WFLA) When Judy Loar, 68, could not bear to walk any longer due to excruciating pain in both of her knees from degenerative joint disease, she did what...

By: Dr. Lox

Excerpt from:
Dr Lox Stem Cell Therapy WFLA News 8 - Video

Recommendation and review posted by simmons

ovation hair - regrow hair - scalp med - Dr. Ari Arumugam - Cosmetic Surgery Chennai -
ovation hair - regrow hair - scalp med - Dr. Ari Arumugam - Cosmetic Surgery Chennai - Dr. Ari Chennaihttp://cosmeticsurgerychennaiindia.com/?-click-here-for-more-info-100194 Industry (Quotation...

By: mathewravisri-hair-transplant

View original post here:
ovation hair - regrow hair - scalp med - Dr. Ari Arumugam - Cosmetic Surgery Chennai - - Video

Recommendation and review posted by Bethany Smith

Dr. Lox, 8 WFLA News, Stem Cell Therapy
Dr. Lox | http://www.drlox.com | 727-462-5582 "It was like a miracle" - Watch as Judy Loar describes her experience with Dr. Dennis Lox to WFLA #39;s Gayle Guyardo.

By: Dr. Lox

Read more:
Dr. Lox, 8 WFLA News, Stem Cell Therapy - Video

Recommendation and review posted by Bethany Smith

Study shows promise for virus specific T cell therapy following bone marrow transplant
Researchers in the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children #39;s Hospital and Houston Methodist Hospital published new res...

By: BCMweb

Read more:
Study shows promise for virus specific T cell therapy following bone marrow transplant - Video

Recommendation and review posted by Bethany Smith

Doctors at Care Fertility, the biggest private provider of IVF treatment, found the faulty gene, known as C4M2, in 44 per cent of their patients compared with just 15 per cent of the general population.

Prof Simon Fishel, managing director, said the gene could be a major cause of recurrent miscarriage.

With proper treatment the number of couples having healthy babies increased to 38 per cent, a similar proportion to other infertility patients of the same age.

The findings were published in the journal Reproductive Biomedicine Online.

The fault means the embryo is unlikely to implant in the womb and if it does it may do so insufficiently, causing late miscarriage or growth problems in the baby.

If the women is the carrier of the faulty gene she is also at risk of complications such as blood clots.

Prof Fishel, lead author on the publication, said Very recently a new genetic marker has been found that predisposes couples to the risk of miscarriage, which we call the C4/M2 variant.

"In addition to the risk of implantation failure and miscarriage, it is linked to blood clotting disorders, pre-eclampsia and low birth weight babies.

"What I do find remarkable, is that in the population of patients studied, the man has the same chance as the woman to pass on this variant to the developing embryo and disturb successful implantation. Where the genetic variant exists, the chance of delivering a baby is reduced to one in four that of fertile couples."

Care Fertility now intend to screen selected patients for the faulty gene so they can be treated appropriately.

Link:
Faulty gene is a major cause of repeated miscarriages, say experts

Recommendation and review posted by Bethany Smith

Free Perfect Genetic Engineering Idea- Changing Spermatogonia and Gametogonia
Came up with idea after a game of basketball and a near asthma attack. Took 3 hours of research but I find it is the easiest solution.

By: Diallo Burke

Go here to see the original:
Free Perfect Genetic Engineering Idea- Changing Spermatogonia and Gametogonia - Video

Recommendation and review posted by Bethany Smith

Let #39;s Play The Sims 3 - Perfect Genetics Challenge: Cowgirl and Horse Edition Episode 7
Come join me on my latest journey into the complex world of sims 3 genetics, as I try to get perfect foals and perfect children. Will I succeed in getting pe...

By: GamerGirlsNetwork

Read more from the original source:
Let's Play The Sims 3 - Perfect Genetics Challenge: Cowgirl and Horse Edition Episode 7 - Video

Recommendation and review posted by Bethany Smith

Let #39;s Play The Sims 3 - Perfect Genetics Challenge: Cowgirl and Horse Edition Episode 8
Come join me on my latest journey into the complex world of sims 3 genetics, as I try to get perfect foals and perfect children. Will I succeed in getting pe...

By: GamerGirlsNetwork

Read more from the original source:
Let's Play The Sims 3 - Perfect Genetics Challenge: Cowgirl and Horse Edition Episode 8 - Video

Recommendation and review posted by Bethany Smith

Genetics of sickle-cell anemia
Sickle cell disease is a disorder that affects the red blood cells, which use a protein called hemoglobin to transport oxygen from the lungs to the rest of the body. Normally, red blood cells...

By: GeneticsLessons

Follow this link:
Genetics of sickle-cell anemia - Video

Recommendation and review posted by Bethany Smith

New Sims 4 | Traits | Genetics | Aspirations
Hope you enjoy the video! Video: https://www.youtube.com/watch?v=4nrEtPITILU Rise of the Dark Ones Trailer: http://www.youtube.com/watch?v=sLZIopOMwo0 Get Pa...

By: Sims3loser, The Awkward Simmer

See original here:
New Sims 4 | Traits | Genetics | Aspirations - Video

Recommendation and review posted by Bethany Smith